Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 1999;34:171-175

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Campbell, D. J.
Right arrow Articles by Kladis, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Campbell, D. J.
Right arrow Articles by Kladis, A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Biochemistry and metabolism
Right arrow Cardiovascular Pharmacology
Right arrow ACE/Angiotension receptors

(Hypertension. 1999;34:171-175.)
© 1999 American Heart Association, Inc.


Scientific Contributions

Angiotensin-Converting Enzyme Inhibition Modifies Angiotensin but Not Kinin Peptide Levels in Human Atrial Tissue

Duncan J. Campbell; Ann-Maree Duncan; Athena Kladis

From St Vincent's Institute of Medical Research, Victoria, Australia.

Correspondence to Dr DJ Campbell, St Vincent's Institute of Medical Research, 41 Victoria Parade, Fitzroy, Victoria 3065, Australia. E-mail j.campbell{at}medicine.unimelb.edu.au

Abstract—Angiotensin-converting enzyme (ACE) converts angiotensin I (Ang I) to angiotensin II (Ang II) and metabolizes bradykinin and kallidin peptides. Decreased Ang II levels and increased kinin peptide levels are implicated in the mediation of the therapeutic effects of ACE inhibition. However, alternative non-ACE pathways of Ang II formation have been proposed to predominate in human heart. We investigated the effects of ACE inhibition on cardiac tissue levels of angiotensin and kinin peptides. High-performance liquid chromatography–based radioimmunoassays were used to measure angiotensin peptides and hydroxylated and nonhydroxylated bradykinin and kallidin peptides in right atrial appendages of subjects who had been prepared for cardiopulmonary bypass. Peptide levels in subjects who received ACE inhibitor therapy were compared with those who did not receive ACE inhibitor therapy. ACE inhibition reduced Ang II levels, which was associated with an 80% reduction in the Ang II/Ang I ratio. ACE inhibition did not modify either bradykinin or kallidin peptide levels or the bradykinin-(1-7)/bradykinin-(1-9) ratio. The 80% reduction in the Ang II/Ang I ratio by ACE inhibition indicated a primary role for ACE in the conversion of Ang I to Ang II in atrial tissue. These data support a role for reduced Ang II levels but do not support a role for increased kinin peptide levels in mediating the direct cardiac effects of ACE inhibition.


Key Words: angiotensin • bradykinin • kallidin • angiotensin-converting enzyme • heart




This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
L. Rosivall and J. Peti-Peterdi
Heterogeneity of the afferent arteriole--correlations between morphology and function
Nephrol. Dial. Transplant., November 1, 2006; 21(11): 3346 - 3346.
[Full Text] [PDF]


Home page
HypertensionHome page
K. B. Brosnihan, L. A.A. Neves, and M. C. Chappell
Does the Angiotensin-Converting Enzyme (ACE)/ACE2 Balance Contribute to the Fate of Angiotensin Peptides in Programmed Hypertension?
Hypertension, November 1, 2005; 46(5): 1097 - 1099.
[Full Text] [PDF]


Home page
HypertensionHome page
D. J. Campbell, T. Alexiou, H. D. Xiao, S. Fuchs, M. J. McKinley, P. Corvol, and K. E. Bernstein
Effect of Reduced Angiotensin-Converting Enzyme Gene Expression and Angiotensin-Converting Enzyme Inhibition on Angiotensin and Bradykinin Peptide Levels in Mice
Hypertension, April 1, 2004; 43(4): 854 - 859.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
D. J. Campbell, B. Dixon, A. Kladis, M. Kemme, and J. D. Santamaria
Activation of the kallikrein-kinin system by cardiopulmonary bypass in humans
Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2001; 281(4): R1059 - R1070.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
B. Tom, R. de Vries, P. R. Saxena, and A.H. J. Danser
Bradykinin Potentiation by Angiotensin-(1-7) and ACE Inhibitors Correlates With ACE C- and N-Domain Blockade
Hypertension, July 1, 2001; 38(1): 95 - 99.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
A.-M. Duncan, A. Kladis, G. L. Jennings, A. M. Dart, M. Esler, and D. J. Campbell
Kinins in humans
Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2000; 278(4): R897 - R904.
[Abstract] [Full Text] [PDF]